Evidence map›Paper›PMID 34228458›Full record

ArticleMolecular pharmaceutics2021

Lara García-Varela, Manuel Rodríguez-Pérez, Antía Custodia, Rodrigo Moraga-Amaro, Nicola A Colabufo, Pablo Aguiar, Tomás Sobrino, Rudi A J O Dierckx, Aren van Waarde, Philip H Elsinga and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Designing a Small Molecule for PET Radiotracing: [Molecules (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Review
  5. Quantification of P-glycoprotein function at the human blood-brain barrier using [European journal of nuclear medicine and molecular imaging · 2023
    Article
  6. Review
  7. Review
  8. First clinical assessment of [Annals of nuclear medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Lara García-VarelaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-9803-4708
Manuel Rodríguez-PérezClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Antía CustodiaClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Rodrigo Moraga-AmaroDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands.
Nicola A ColabufoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari, I-70125 Bari, Italy.ORCID 0000-0001-5639-7746
Pablo AguiarDepartment of Nuclear Medicine and Molecular Imaging Group, Clinical University Hospital, IDIS Health Research Institute, 15706 Santiago de Compostela, Spain.
Tomás SobrinoClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-9760-8690
Rudi A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands.
Aren van WaardeDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands.
Philip H ElsingaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands.
Gert LuurtsemaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9713 GZ Groningen, The Netherlands.
University Medical Center Groningen · NLInstituto de Investigación Sanitaria de Santiago · ESUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

P-Glycoprotein (P-gp) is an efflux pump located at the blood-brain barrier (BBB) that contributes to the protection of the central nervous system by transporting neurotoxic compounds out of the brain. A decline in P-gp function has been related to the pathogenesis of neurodegenerative diseases. P-gp inducers can increase the P-gp function and are considered as potential candidates for the treatment of such disorders. The P-gp inducer MC111 increased P-gp expression and function in SW480 human colon adenocarcinoma and colo-320 cells, respectively. Our study aims to evaluate the P-gp inducing effect of MC111 in the whole brain

Indexed as

AnimalsATP Binding Cassette Transporter, Subfamily B, Member 1Biological TransportBlood-Brain BarrierEndothelial CellsIsoquinolinesKineticsMalePositron-Emission TomographyRadiopharmaceuticalsRatsRats, WistarTetrahydronaphthalenesATP Binding Cassette Transporter, Subfamily B, Member 1IsoquinolinesMC225 compoundRadiopharmaceuticalsTetrahydronaphthalenesABC transportersbrain Imagingefflux transportersP-glycoproteinP-gp inducers

Identifiers

PMID34228458
PMCPMC8383301
OpenAlexW3182206694

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.